Here's Why Arrowhead Pharmaceuticals Stock Jumped 34% in June
Shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) rose 34% last month, according to data provided by S&P Global Market Intelligence. That far outpaced the less than 2% gains of the S&P 500 and the NASDAQ Biotechnology Index.
There wasn't any company-specific news to drive shares higher, but after the slide they took early in 2020 -- a rough period that began for Arrowhead before the coronavirus pandemic seized Wall Street's attention -- investors probably aren't complaining. Considering the company initiated multiple new clinical trials in the first half of the year, there's reason to expect the pharma stock can hang onto its recent gains.
Image source: Getty Images.
Source Fool.com
